Eisai Posts First Ever Net Loss Due To Heavy Investment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961
You may also be interested in...
Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs
Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher
Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs
Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher
MHLW Approves Abbott’s Humira To Be Distributed By Eisai In Japan
TOKYO - In contrast to wide criticisms about long drug lags in Japan, the Ministry of Health, Labor and Welfare has approved Abbott's rheumatoid arthritis antibody drug Humira (adalimumab) to be distributed by Eisai in Japan, the two companies announced June 17